AAAAAA

   
Results: 1-25 | 26-34
Results: 1-25/34
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals
Authors: Veldkamp, AI van Heeswijk, RPG Mulder, JW Meenhorst, PL Schreij, G van der Geest, S Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Ai. Veldkamp et al., Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals, J ACQ IMM D, 27(4), 2001, pp. 344-349
A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy
Authors: Burger, DM Hugen, PWH Aarnoutse, RE Dieleman, JP Prins, JM van der Poll, T ten Veen, JH Mulder, JW Meenhorst, PL Blok, WL van der Meer, JTM Reiss, P Lange, JMA
Citation: Dm. Burger et al., A retrospective, cohort-based survey of patients using twice-daily indinavir plus ritonavir combinations: Pharmacokinetics, safety, and efficacy, J ACQ IMM D, 26(3), 2001, pp. 218-224
Untitled
Authors: Knottnerus, AC de Jong, DJA Haumann, TJ Mulder, JW
Citation: Ac. Knottnerus et al., Untitled, CLEF PAL-CR, 38(3), 2001, pp. 284-284
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals
Authors: Koks, CHW Crommentuyn, KML Hoetelmans, RMW Burger, DM Koopmans, PP Mathot, RAA Mulder, JW Meenhorst, PL Beijnen, JH
Citation: Chw. Koks et al., The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals, BR J CL PH, 51(6), 2001, pp. 631-635
Overview: full scale experience of the SHARON (R) process for treatment ofrejection water of digested sludge dewatering
Authors: van Kempen, R Mulder, JW Uijterlinde, CA Loosdrecht, MCM
Citation: R. Van Kempen et al., Overview: full scale experience of the SHARON (R) process for treatment ofrejection water of digested sludge dewatering, WATER SCI T, 44(1), 2001, pp. 145-152
Full-scale application of the SHARON process for treatment of rejection water of digested sludge dewatering
Authors: Mulder, JW van Loosdrecht, MCM Hellinga, C van Kempen, R
Citation: Jw. Mulder et al., Full-scale application of the SHARON process for treatment of rejection water of digested sludge dewatering, WATER SCI T, 43(11), 2001, pp. 127-134
Drug interaction between St John's wort and nevirapine
Authors: de Maat, MMR Hoetelmans, RMW Mathot, RAA van Gorp, ECM Meenhorst, PL Mulder, JW Beijnen, JH
Citation: Mmr. De Maat et al., Drug interaction between St John's wort and nevirapine, AIDS, 15(3), 2001, pp. 420-421
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy
Authors: Reijers, MHE Weverling, GJ Jurriaans, S Roos, MTL Wit, FWNM Weigel, HM Ten Kate, RW Mulder, JW Richter, C Ter Hofstede, HJM Sprenger, H Hoetelmans, RMW Schuitemaker, H Lange, JMA
Citation: Mhe. Reijers et al., The ADAM study continued: maintenance therapy after 50 weeks of induction therapy, AIDS, 15(1), 2001, pp. 129-131
Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine
Authors: Veldkamp, AI van Heeswijk, RPG Mulder, JW Meenhorst, PL Hoetelmans, RMW Lange, JMA Beijnen, JH
Citation: Ai. Veldkamp et al., Limited sampling strategies for the estimation of the systemic exposure tothe HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine, THER DRUG M, 23(6), 2001, pp. 606-611
Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Beijnen, JH Lange, JMA Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Saliva as an alternative body fluid for therapeutic drug monitoring of thenonnucleoside reverse transcription inhibitor nevirapine, THER DRUG M, 23(3), 2001, pp. 255-258
Nevirapine plus didanosine: Once or twice daily combination?
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Reiss, P Lange, JMA Kwakkelstein, MO Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Nevirapine plus didanosine: Once or twice daily combination?, J ACQ IMM D, 25(1), 2000, pp. 93-95
Aplasia cutis of the scalp: a report of two cases
Authors: Beekmans, SJA Mulder, JW
Citation: Sja. Beekmans et Jw. Mulder, Aplasia cutis of the scalp: a report of two cases, EUR J PLAST, 23(4), 2000, pp. 245-247
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study, AIDS, 14(9), 2000, pp. F103-F110
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
Authors: van Heeswijk, RPG Veldkamp, AI Mulder, JW Meenhorst, PL Wit, FWNM Lange, JMA Danner, SA Foudraine, NA Kwakkelstein, MO Reiss, P Beijnen, JH Hoetelmans, RMW
Citation: Rpg. Van Heeswijk et al., The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals, AIDS, 14(8), 2000, pp. F77-F82
Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study
Authors: Reijers, MHE Weigel, HM Hart, AAM Ten Kate, RW Mulder, JW Reiss, P Schuitemaker, H Hoetelmans, RMW Weverling, GJ Lange, JMA
Citation: Mhe. Reijers et al., Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study, AIDS, 14(1), 2000, pp. 59-68
Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir
Authors: Koks, CHW van Heeswijk, RPG Veldkamp, AI Meenhorst, PL Mulder, JW van der Meer, JTM Beijnen, JH Hoetelmans, RMW
Citation: Chw. Koks et al., Itraconazole as an alternative for ritonavir liquid formulation when combined with saquinavir, AIDS, 14(1), 2000, pp. 89-90
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir
Authors: Hugen, PWH Burger, DM de Graaff, M ter Hofstede, HJM Hoetelmans, RMW Brinkman, K Meenhorst, PL Mulder, JW Koopmans, PP Hekster, YA
Citation: Pwh. Hugen et al., Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir, THER DRUG M, 22(4), 2000, pp. 437-445
Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men
Authors: Kanhai, RCJ Hage, JJ van Diest, PJ Bloemena, E Mulder, JW
Citation: Rcj. Kanhai et al., Short-term and long-term histologic effects of castration and estrogen treatment on breast tissue of 14 male-to-female transsexuals in comparison with two chemically castrated men, AM J SURG P, 24(1), 2000, pp. 74-80
Value of different assays for detection of human cytomegalovirus (HCMV) inpredicting the development of HCMV disease in human immunodeficiency virus-infected patients
Authors: Blank, BSN Meenhorst, PL Mulder, JW Weverling, GJ Putter, H Pauw, W van Dijk, WC Smits, P Lie-A-Ling, S Reiss, P Lange, JMA
Citation: Bsn. Blank et al., Value of different assays for detection of human cytomegalovirus (HCMV) inpredicting the development of HCMV disease in human immunodeficiency virus-infected patients, J CLIN MICR, 38(2), 2000, pp. 563-569
Long-term outcome of augmentation mammaplasty in male-to-female transsexuals: a questionnaire survey of 107 patients
Authors: Kanhai, RCJ Hage, JJ Mulder, JW
Citation: Rcj. Kanhai et al., Long-term outcome of augmentation mammaplasty in male-to-female transsexuals: a questionnaire survey of 107 patients, BR J PL SUR, 53(3), 2000, pp. 209-211
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
Authors: Veldkamp, AI van Heeswijk, RPG Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH Hoetelmans, RMW
Citation: Ai. Veldkamp et al., Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection, J CHROMAT B, 734(1), 1999, pp. 55-61
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection
Authors: Veldkamp, AI van Heeswijk, RPG Hoetelmans, RMW Meenhorst, PL Mulder, JW Lange, JMA Beijnen, JH
Citation: Ai. Veldkamp et al., Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection, J CHROMAT B, 727(1-2), 1999, pp. 151-157
Ritonavir enables combined therapy with rifampin and saquinavir
Authors: Veldkamp, AI Hoetelmans, RMW Beijnen, JH Mulder, JW Meenhorst, PL
Citation: Ai. Veldkamp et al., Ritonavir enables combined therapy with rifampin and saquinavir, CLIN INF D, 29(6), 1999, pp. 1586-1586
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial
Authors: Been-Tiktak, AMM Boucher, CAB Brun-Vezinet, F Joly, V Mulder, JW Jost, J Cooper, DA Moroni, M Gatell, JM Staszewski, S Colebunders, R Stewart, GJ Hawkins, DA Johnson, MA Parkin, JM Kennedy, DH Hoy, JF Borleffs, JCC
Citation: Amm. Been-tiktak et al., Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial, INT J ANT A, 11(1), 1999, pp. 13-21
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma - drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study
Authors: Panday, VRN Hoetelmans, RMW van Heeswijk, RPG Meenhorst, PL Inghels, M Mulder, JW Beijnen, JH
Citation: Vrn. Panday et al., Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma - drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study, CANC CHEMOT, 43(6), 1999, pp. 516-519
Risultati: 1-25 | 26-34